Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Long-Term Deferred Tax: 2017-2020

  • Summit Therapeutics' Long-Term Deferred Tax fell 570.08% to -$189,716 in Q1 2020 from the same period last year, while for Mar 2020 it was -$189,716, marking a year-over-year decrease of 570.08%. This contributed to the annual value of $133.89 for FY2017, which is N/A change from last year.
  • Summit Therapeutics' Long-Term Deferred Tax amounted to -$189,716 in Q1 2020, which was down 337.52% from $79,875 recorded in Q3 2019.
  • Summit Therapeutics' 5-year Long-Term Deferred Tax high stood at $752,966 for Q3 2018, and its period low was -$189,716 during Q1 2020.
  • Moreover, its 3-year median value for Long-Term Deferred Tax was $60,117 (2019), whereas its average is $170,871.
  • Data for Summit Therapeutics' Long-Term Deferred Tax shows a maximum YoY crashed of 570.08% (in 2020) over the last 5 years.
  • Summit Therapeutics' Long-Term Deferred Tax (Quarterly) stood at $124.12 in 2017, then reached $752,966 in 2018, then crashed by 89.39% to $79,875 in 2019, then tumbled by 570.08% to -$189,716 in 2020.
  • Its last three reported values are -$189,716 in Q1 2020, $79,875 for Q3 2019, and $40,358 during Q1 2019.